Search research articles
Contact Us
Filters
Showing results (1-10 of 58) with videos related to
Page
of 6
Sort By:
Therapeutic Advances in Gastroenterology
|
January 16, 2013
Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma
Chris Probert
Alimentary Pharmacology & Therapeutics
|
December 19, 2019
Commentary: vitamin D supplementation in Crohn's disease
Chris Probert
Digestive Diseases (Basel, Switzerland)
|
June 28, 2014
Future methods for the diagnosis of inflammatory bowel disease
Raphael Aggio, Chris Probert
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 21, 2014
Population-based screening in colorectal cancer - current practice and future developments: faecal biomarkers review
David Sawbridge, Chris Probert
Alimentary Pharmacology & Therapeutics
|
March 29, 2019
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply
Ashley Bond, Chris Probert
Inflammatory Bowel Diseases
|
June 12, 2003
A Crohn's repertoire: T cell receptor gammadelta
Trevor Brooklyn, Chris Probert
Frontline Gastroenterology
|
August 26, 2017
Managing acute severe ulcerative colitis in the hosptialised setting
David McClements, Chris Probert
Alimentary Pharmacology & Therapeutics
|
June 28, 2020
Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research
Tristan Townsend, Chris Probert
BMJ (Clinical Research Ed.)
|
July 22, 2006
Diagnosis and treatment of pyoderma gangrenosum
Trevor Brooklyn, Giles Dunnill, Chris Probert
Frontline Gastroenterology
|
August 26, 2017
Biosimilars: what's around the corner?
Richard K Russell, Peter Irving, Chris Probert
Page
of 6
Search research articles
Search
Showing results (1-10 of 58) with videos related to
Sort By:
Page
of 6
Therapeutic Advances in Gastroenterology
|
January 16, 2013
Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma
Chris Probert
Alimentary Pharmacology & Therapeutics
|
December 19, 2019
Commentary: vitamin D supplementation in Crohn's disease
Chris Probert
Digestive Diseases (Basel, Switzerland)
|
June 28, 2014
Future methods for the diagnosis of inflammatory bowel disease
Raphael Aggio, Chris Probert
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 21, 2014
Population-based screening in colorectal cancer - current practice and future developments: faecal biomarkers review
David Sawbridge, Chris Probert
Alimentary Pharmacology & Therapeutics
|
March 29, 2019
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply
Ashley Bond, Chris Probert
Inflammatory Bowel Diseases
|
June 12, 2003
A Crohn's repertoire: T cell receptor gammadelta
Trevor Brooklyn, Chris Probert
Frontline Gastroenterology
|
August 26, 2017
Managing acute severe ulcerative colitis in the hosptialised setting
David McClements, Chris Probert
Alimentary Pharmacology & Therapeutics
|
June 28, 2020
Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research
Tristan Townsend, Chris Probert
BMJ (Clinical Research Ed.)
|
July 22, 2006
Diagnosis and treatment of pyoderma gangrenosum
Trevor Brooklyn, Giles Dunnill, Chris Probert
Frontline Gastroenterology
|
August 26, 2017
Biosimilars: what's around the corner?
Richard K Russell, Peter Irving, Chris Probert
Page
of 6